Clinical trial
Combined Use of BCG and Interferon Alpha in Bladder Cancer
NCT00330707 · National University Hospital, Singapore, Other · Completed
Key facts
| NCT number | NCT00330707 |
|---|---|
| Title | Combined Use of BCG and Interferon Alpha in Bladder Cancer |
| Official title | A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer |
| Lead sponsor | National University Hospital, Singapore, Other |
| Collaborators | National Medical Research Council (NMRC), Singapore |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma of Urinary Bladder, Superficial |
| Intervention type | Drug |
| Interventions | Bacillus Calmette Guerin and interferon alpha |
| Enrollment | 140 |
| Start date | Oct 1, 1995 |
| Completion | Jun 1, 2005 |
| First posted | May 29, 2006 |
| Last update posted | Mar 4, 2011 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: